Health Law & Business News

Gilead’s Remdesivir Helped Only Those on Oxygen, Study Says

May 22, 2020, 10:25 PM

Gilead Sciences Inc.’s remdesivir, which was authorized to treat Covid-29 in adults and children who need supplemental oxygen, a ventilator or extracorporeal membrane oxygenation (ECMO), only helps those on supplmental oxygen, not the latter two types, a study by the New England Journal of Medicine said.

  • ”Our findings highlight the need to identify Covid-19 cases and start antiviral treatment before the pulmonary disease progresses to require mechanical ventilation,” the researchers said.
  • Only patients who were receiving supplemental oxygen derived significant benefit in the study
  • No marked benefit seen for those who were healthier and didn’t need oxygen or those who...

To read the full article log in. To learn more about a subscription click here.